Sanofi Pasteur is working with the US Biomedical Advanced Research and Development Authority (BARDA) to develop a vaccine against the novel coronavirus, known as severe acute respiratory syndrome-CoV-2, which as of Feb 20 had infected more than 75,000 people and killed more than 2,100 Sanofi will build on work on a vaccine against SARS, another coronavirus that circulated in the early 2000s In December 2019, BARDA awarded the firm a $226 million contract to expand manufacturing capacity for use in a potential flu pandemic Sanofi says the new vaccine will use the same technology